Search

Background Parkinson's disease (PD) is associated with α-synuclein (αS) aggregation within the enteric nervous system (ENS) and constipation. Squalamine displaces proteins that are electrostatically bound to intracellular membranes and through this mechanism suppresses aggregation of αS monomers into neurotoxic oligomers. Objective We sought to evaluate the safety of ENT-01 oral tablets (a synthetic squalamine salt), its pharmacokinetics, and its effect on bowel function in PD patients with constipation. Methods In Stage 1, 10 patients received escalating single doses from 25 to 200 mg/day or maximum tolerated dose (MTD). In Stage 2, 34 patients received daily doses escalating from 75 to a maximum of 250 mg/day, a dose that induced change in bowel function or MTD, followed by a fixed dose for 7 days, and a 2-week washout. Primary efficacy endpoint was defined as an increase of 1 complete spontaneous bowel movement (CSBM)/week, or 3 CSBM/week over the baseline period, as defined by FDA guidelines for prokinetic agents. Safety was also assessed. Results Over 80% of patients achieved the primary efficacy endpoint, with the mean number of CSBM/week increasing from 1.2 at baseline to 3.6 during fixed dosing (p = 1.2 × 10−7). Common adverse events included nausea in 21/44 (47%) and diarrhea in 18/44 (40%) patients. Systemic absorption was Conclusions Orally administered ENT-01 was safe and significantly improved bowel function in PD, suggesting that the ENS is not irreversibly damaged in PD. Minimal systemic absorption suggests that improvements result from local stimulation of the ENS. A double-blind, placebo-controlled study is now ongoing.

Traditional hypotheses for the pathogenesis of dystonia, the third most common movement disorder, have focused primarily on the basal ganglia. Contemporary theories have emphasized the role of the cerebellum. The modulation of peripheral proprioception also affects dystonia. We proposed a unifying network model for dystonia where the cerebellum, basal ganglia, and peripheral proprioception are connected in a circuit that forms the neural integrator network, ensuring steady position. We suggested that impairment anywhere along this circuit leads to common phenomenology-slow drifts followed by corrective movements, resembling dystonic tremor. We tested this concept in a patient with chronic inflammatory demyelinating polyneuropathy with resulting abnormal proprioception. Quantitative assessment of tremor in this patient revealed drifts in limb position followed by corrective movements and superimposed sinusoidal oscillations-consistent with neural integrator dysfunction. This unique case of chronic inflammatory demyelinating polyneuropathy describes the role of proprioception on the unifying network model for dystonia.

Publisher Summary The understanding of the pathophysiology of the Parkinson's disease (PD), advances in surgical technique, and the development of imaging technology has led to the development of current surgical approaches for the treatment of this disease. This chapter reviews early empirical studies of surgical therapy and the evolution that has led to present neurosurgical approaches for the treatment of PD. These includes the effects of retrograde anatomical tracing studies in the hands of Hassler, implementation of the stereotaxis, advancements in neuroradiology from early ventriculography to CT and magnetic resonance imaging (MRI). Also important are the implementation of microelectrode physiology, the development of neurostimulator technologies, and now gene and transplant therapies. Advances in neuroscience have played a crucial role in the progress of this field, laying the groundwork for the understanding of the separate functions of the pyramidal and extrapyramidal motor systems, the role of dopaminergic neurons in PD.